XTL Biopharmaceuticals To Focus On Core Asset SLE/Lupus And Multiple Myeloma Drugs
Raanana, Israel based XTL Biopharmaceuticals Ltd. (XTL)Â has announced that following evaluation of market opportunity for its pipeline products its decision to focus efforts and expenditures exclusively on two core assets: hCDR1 for treatment of SLE/lupus and rHuEPO for “no-option” multiple myeloma patients. XTL, whose shares are traded on the…